VEETIDS '250'

Pre-Launch

penicillin v potassium

ANDAORALFOR SOLUTION

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

VEETIDS '250' (penicillin v potassium) by Bristol Myers Squibb is clinical pharmacology penicillin v exerts a bactericidal action against penicillin-sensitive microorganisms during the stage of active multiplication. Approved for the treatment of mild to moderately severe infections due to penicillin g-sensitive microorganisms.

Drug data last refreshed 1mo ago

Mechanism of Action

CLINICAL PHARMACOLOGY Penicillin V exerts a bactericidal action against penicillin-sensitive microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall mucopeptide. It is not active against the penicillinase-producing bacteria, which…

Indications (1)

Worked on VEETIDS '250' at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.